Vaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causes
To study efficiency of molgramostim as an adjuvant in HBV vaccination we randomized 18 pts after OLT due to non-HBV causes. Nine pts received GM-CSF (150 mcg of sc 24 h before 1st dose of vaccine). Other 9 pts received only vaccine. Both groups of pts did not differ in sex, age, immunosuppression an...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department
2018-08-01
|
| Series: | Трансплантология (Москва) |
| Subjects: | |
| Online Access: | https://www.jtransplantologiya.ru/jour/article/view/289 |
| _version_ | 1797702846105255936 |
|---|---|
| author | V. E. Syutkin A. A. Saliyenko D. E. Syutkina A. V. Chzhao |
| author_facet | V. E. Syutkin A. A. Saliyenko D. E. Syutkina A. V. Chzhao |
| author_sort | V. E. Syutkin |
| collection | DOAJ |
| description | To study efficiency of molgramostim as an adjuvant in HBV vaccination we randomized 18 pts after OLT due to non-HBV causes. Nine pts received GM-CSF (150 mcg of sc 24 h before 1st dose of vaccine). Other 9 pts received only vaccine. Both groups of pts did not differ in sex, age, immunosuppression and received vaccine in double doses (40 mcg im) by similar way (0, 1 and 2 Mo). Anti-HBs titers were estimated in 3 Mo after the last dose of vaccine. High anti-HBs titer (>200 mME/ml) achieved 4 pts (44%) from the GM-CSF group and nobody from the control group (p=0.037) No serious adverse effects occurred. Conclusion: GM-CSF may be useful as an adjuvant in HBV vaccination after OLT. |
| first_indexed | 2024-03-12T04:55:51Z |
| format | Article |
| id | doaj.art-82d88b4dbaa14b3c9c3d056886e0f82c |
| institution | Directory Open Access Journal |
| issn | 2074-0506 2542-0909 |
| language | English |
| last_indexed | 2024-03-12T04:55:51Z |
| publishDate | 2018-08-01 |
| publisher | N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department |
| record_format | Article |
| series | Трансплантология (Москва) |
| spelling | doaj.art-82d88b4dbaa14b3c9c3d056886e0f82c2023-09-03T09:15:14ZengN.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare DepartmentТрансплантология (Москва)2074-05062542-09092018-08-0103-4182210.23873/2074-0506-2010-0-3-4-18-22278Vaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causesV. E. Syutkin0A. A. Saliyenko1D. E. Syutkina2A. V. Chzhao3Московский центр трансплантации печени НИИ скорой помощи им. Н.В. СклифосовскогоМосковский центр трансплантации печени НИИ скорой помощи им. Н.В. СклифосовскогоМосковский центр трансплантации печени НИИ скорой помощи им. Н.В. СклифосовскогоМосковский центр трансплантации печени НИИ скорой помощи им. Н.В. СклифосовскогоTo study efficiency of molgramostim as an adjuvant in HBV vaccination we randomized 18 pts after OLT due to non-HBV causes. Nine pts received GM-CSF (150 mcg of sc 24 h before 1st dose of vaccine). Other 9 pts received only vaccine. Both groups of pts did not differ in sex, age, immunosuppression and received vaccine in double doses (40 mcg im) by similar way (0, 1 and 2 Mo). Anti-HBs titers were estimated in 3 Mo after the last dose of vaccine. High anti-HBs titer (>200 mME/ml) achieved 4 pts (44%) from the GM-CSF group and nobody from the control group (p=0.037) No serious adverse effects occurred. Conclusion: GM-CSF may be useful as an adjuvant in HBV vaccination after OLT.https://www.jtransplantologiya.ru/jour/article/view/289вакцинациягепатит вортотопическая трансплантация печенимолграмостимгранулоцитарномакрофагальный колониестимулирующий фактор |
| spellingShingle | V. E. Syutkin A. A. Saliyenko D. E. Syutkina A. V. Chzhao Vaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causes Трансплантология (Москва) вакцинация гепатит в ортотопическая трансплантация печени молграмостим гранулоцитарномакрофагальный колониестимулирующий фактор |
| title | Vaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causes |
| title_full | Vaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causes |
| title_fullStr | Vaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causes |
| title_full_unstemmed | Vaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causes |
| title_short | Vaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causes |
| title_sort | vaccination against viral hepatitis b in patients undergoing liver transplantation for hepatitis b unassociated causes |
| topic | вакцинация гепатит в ортотопическая трансплантация печени молграмостим гранулоцитарномакрофагальный колониестимулирующий фактор |
| url | https://www.jtransplantologiya.ru/jour/article/view/289 |
| work_keys_str_mv | AT vesyutkin vaccinationagainstviralhepatitisbinpatientsundergoinglivertransplantationforhepatitisbunassociatedcauses AT aasaliyenko vaccinationagainstviralhepatitisbinpatientsundergoinglivertransplantationforhepatitisbunassociatedcauses AT desyutkina vaccinationagainstviralhepatitisbinpatientsundergoinglivertransplantationforhepatitisbunassociatedcauses AT avchzhao vaccinationagainstviralhepatitisbinpatientsundergoinglivertransplantationforhepatitisbunassociatedcauses |